Regeneron Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Shareholders held on June 13, 2025. The filing was submitted on June 18, 2025. Regeneron Pharmaceuticals, Inc. is incorporated in New York and its common stock trades on the NASDAQ Global Select Market under the symbol REGN.
Key Financial Metrics
This filing is a Current Report regarding shareholder voting outcomes and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Shareholders voted on five proposals. Four proposals were approved, while two amendments related to supermajority vote requirements were not approved.
- Proposal 1 (Election of Directors): All four Class I nominees were elected. Notable vote counts included George D. Yancopoulos (101.4M For) and Michael S. Brown (77.0M For, 28.9M Against).
- Proposal 2 (Auditor Ratification): Ratification of PricewaterhouseCoopers LLP was approved (105.5M For, 6.1M Against).
- Proposal 3 (Executive Compensation): The advisory vote on executive compensation was approved (98.8M For, 7.1M Against).
- Proposal 4 (Board Declassification): The amendment to declassify the Board of Directors was approved (85.7M For, 20.2M Against).
- Proposal 5 (Elimination of Supermajority Vote Requirements): Both sub-proposals were not approved.
- 5(a) (Class A Stock Conversion): Failed due to 0 votes For and 18.1M votes Against from Class A stockholders.
- 5(b) (Removal of Directors): Failed to meet the required 80% supermajority threshold (85.5M For, 20.4M Against).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The primary focus is the administrative outcome of the shareholder vote.
Key Facts for Investor Verification
- Verify the implications of the failed Proposal 5, which sought to eliminate supermajority voting requirements for specific corporate actions.
- Note the significant "Against" votes for Michael S. Brown (approx. 27% of votes cast) and the unanimous "Against" vote from Class A stockholders on Proposal 5(a).
- Confirm the successful declassification of the Board of Directors via Proposal 4, which will result in annual elections for all directors.
- Review the definitive proxy statement (Schedule 14A filed April 29, 2025) for detailed context on the executive compensation and director nominees.